SCHEMBL24155459

SCHEMBL24155459

FC(F)(F)c1cn2cc(-c3cnc(Oc4ccccc4)nc3)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.56
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A3 P47895 6/20 0.40
ALDH1A1 P00352 2/20 0.40
ALDH1A2 O94788 1/20 0.40
HPGDS O60760 3/20 0.38
SLC2A1 P11166 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SYK P43405 1/20 0.36
HTT P42858 1/20 0.36
GRM5 P41594 3/20 0.35
PDE10A Q9Y233 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22044438 0.83 MEN1 (0.42) SCN5AMEN1KMT2ANPC1GAA
SCHEMBL24155509 0.81 MEN1 (0.50) MEN1KMT2ANPC1GAARAB9A
SCHEMBL24155466 0.81 KMT2A (0.50) MEN1KMT2ANPC1GAARAB9A
SCHEMBL20208548 0.80 SCN5A (0.68) SCN5AKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL24155835 0.77 MEN1 (0.58) MEN1KMT2ANPC1GAARAB9A
SCHEMBL24156337 0.76 GRM5 (0.46) MEN1KMT2ANPC1GAARAB9A
SCHEMBL24156365 0.76 SCN5A (0.57) SCN5AMEN1KMT2ANPC1GAA
SCHEMBL21995639 0.76 MEN1 (0.52) MEN1KMT2ANPC1GAARAB9A
SCHEMBL22044433 0.74 MEN1 (0.51) SCN5AMEN1KMT2ANPC1GAA
SCHEMBL24155897 0.74 MEN1 (0.47) MEN1KMT2ANPC1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B SCN5A 25/4885MEN1 450/4885KMT2A 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.